{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:26:35Z","timestamp":1772162795260,"version":"3.50.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n                    carbapenemase (KPC)-producing\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    isolates have been increasingly reported worldwide, and therapeutic options to treat infections caused by these organisms are limited. We evaluated the activity of ceftazidime-avibactam and comparators against 456\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    isolates carrying\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    collected from 79 U.S. hospitals during 2012 to 2015. Overall, ceftazidime-avibactam (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.5\/2 \u03bcg\/ml; 99.3% susceptible) and tigecycline (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.5\/1 \u03bcg\/ml; 98.9% susceptible at \u22642 \u03bcg\/ml) were the most active agents. Only 80.5% and 59.0% of isolates were susceptible to colistin and amikacin, respectively. All three isolates (0.7%) displaying resistance to ceftazidime-avibactam (\n                    <jats:named-content content-type=\"genus-species\">K. pneumoniae<\/jats:named-content>\n                    ; MICs, \u226516 \u03bcg\/ml) were evaluated using whole-genome sequencing analysis and relative quantification of expression levels of porins and efflux pump. Two isolates carried metallo-\u03b2-lactamase genes,\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>NDM-1<\/jats:sub>\n                    or\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>VIM-4<\/jats:sub>\n                    , among other \u03b2-lactam resistance mechanisms, and one displayed a premature stop codon in\n                    <jats:italic>ompK35<\/jats:italic>\n                    and decreased expression of\n                    <jats:italic>ompK36<\/jats:italic>\n                    . Ceftazidime-avibactam was active against 100.0 and 99.3% of isolates carrying\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>KPC-3<\/jats:sub>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 221) and\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>KPC-2<\/jats:sub>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    = 145), respectively. Isolates carrying\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    were more commonly recovered from pneumonia (\n                    <jats:italic>n<\/jats:italic>\n                    = 155), urinary tract (\n                    <jats:italic>n<\/jats:italic>\n                    = 93), and skin\/soft tissue (\n                    <jats:italic>n<\/jats:italic>\n                    = 74) infections. Ceftazidime-avibactam (97.8 to 100.0% susceptible) was consistently active against isolates from all infection sites.\n                    <jats:named-content content-type=\"genus-species\">K. pneumoniae<\/jats:named-content>\n                    (83.3% of the collection) susceptibility rates were 99.2% for ceftazidime-avibactam, 98.9% for tigecycline, and 80.1% for colistin. Ceftazidime-avibactam susceptibility did not vary substantially when comparing isolates from intensive care unit (ICU) patients to those from non-ICU patients. Ceftazidime-avibactam was active against this large collection of isolates carrying\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    and represents a valuable addition to the armamentarium currently available for the treatment of infections caused by KPC-producing\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/aac.02369-16","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T21:30:21Z","timestamp":1482960621000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying\n                    <i>bla<\/i>\n                    <sub>KPC<\/sub>\n                    Collected in U.S. Hospitals from 2012 to 2015"],"prefix":"10.1128","volume":"61","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1544208"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00007"},{"key":"e_1_3_2_5_2","unstructured":"FDA. 2015. Avycaz\u00ae (ceftazidime-avibactam) package insert. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494s000lbl.pdf. Accessed March 2016."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1151-1161.2001"},{"key":"e_1_3_2_7_2","unstructured":"CDC. 2015. Tracking CRE infections. http:\/\/www.cdc.gov\/hai\/organisms\/cre\/TrackingCRE.html. Accessed April 2016."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01198-10"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00548-15"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02019-15"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00107-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw398"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01844-15"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.181.9.2726-2732.1999"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4760-4762.2005"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv094"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04406-14"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-15"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01585-15"},{"key":"e_1_3_2_22_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_24_2","unstructured":"Pfizer. 2015. Tygacil\u00ae package insert. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=491. Accessed August 2015."},{"key":"e_1_3_2_25_2","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters version 6.0 January 2016. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2016."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr081"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2012.0021"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-421"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00050-15"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01310-13"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks261"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03930-14"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02369-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02369-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:46:18Z","timestamp":1645458378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02369-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1128\/AAC.02369-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02369-16","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727151742.793536917","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02369-16"}}